Guardant Health Launches Liquid Biopsy Test For Detecting Colorectal Cancer Recurrence
Executive Summary
Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.
You may also be interested in...
PAVmed Plans Spin-Off And Marketing Push For Lucid Diagnostics
Lucid, which markets the EsoGuard test for Barrett’s esophagus, will become a separate public company, either through an IPO or a business combination with a health care SPAC.
Exact Sciences Acquires Ashion Analytics To Accelerate Sequencing Technology
The addition of the Arizona-based sequencing lab builds on Exact’s recent license of the TARDIS liquid biopsy technology from TGen.
JPM 2021: Medtronic, Biogen, Edwards LifeSciences, Guardant Health, Illumina
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
This content is free with registration!
Start a free trial today!
Register to keep reading and receive our free email digests